AAPG
NASDAQAscentage Pharma Group International
News · 26 weeks66-23%
2025-12-142026-06-07
Mix5290d
- Insider25(48%)
- SEC Filings13(25%)
- Offering11(21%)
- Analyst2(4%)
- Other1(2%)
Latest news
25 items- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) were presented i
- PRAscentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Soc
- PRAscentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting is t
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- INSIDERChief Medical Officer Zhai Yifan converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 30% to 405,280 units (SEC Form 4)4 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERChairman and CEO Yang Dajun converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 9% to 1,193,569 units (SEC Form 4)4 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO's official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association CongressROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for cancers and other diseases, announced today that 17 clinical advances of its core assets will be featured at the 31st Congress of the European Hematology Association (EHA2026), including 8 poster presentations. The abstracts feature data from ongoing clinical studies encompassing Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bc
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Participate in Three Upcoming Investor ConferencesROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences. B. Riley Commercial/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18thStifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19thJefferies G
- SECSEC Form 20-F filed by Ascentage Pharma Group International20-F - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- ANALYSTDeutsche Bank initiated coverage on Ascentage Pharma with a new price targetDeutsche Bank initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $40.00
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstrac
- INSIDERSEC Form 4 filed by Misra Veet4 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Misra Veet3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Cao Jin3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual MeetingROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA. These posters feature three of the Company's drug candidates, Olverembatinib (HQP1351), a novel BCR-ABL inhibitor; APG-2449, a FAK/ALK/ROS1 triple tyrosine kinase
- INSIDERSEC Form 3 filed by new insider Cao Jin3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
AAPG FAQ
6 questionsWhere does AAPG stock trade?
Ascentage Pharma Group International (AAPG) is listed on NASDAQ.What sector and industry is AAPG in?
Ascentage Pharma Group International operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascentage Pharma Group International go public?
Ascentage Pharma Group International (AAPG) completed its IPO in 2025.What are analysts saying about AAPG?
Ascentage Pharma Group International has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy with a $4000.00 price target on 2026-04-24. Recent price targets range from $4000.00 to $4800.00.What companies are similar to AAPG?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AAPG side-by-side with any of them on Quantisnow.How can I track AAPG on Quantisnow?
Quantisnow aggregates Ascentage Pharma Group International's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AAPG to receive live email and push alerts on every new disclosure.